P.S.K Biosciences Presents Progress in Engineered Exosome-Based CNS Delivery at BIOCHINA2026

BIOCHINA2026, the 11th EBC Biopharma Industry Exhibition, was held in Suzhou from March 12 to 14, 2026. Dr. Tinghe Wu, Founder and CEO of P.S.K Biosciences, was invited to attend the event and delivered a presentation at the Exosome Development and Innovation Forum.

The presentation was titled “Engineered Exosomes Crossing the Blood–Brain Barrier: A New Paradigm for CNS Nucleic Acid Delivery.” Dr. Wu discussed key challenges in nucleic acid delivery for central nervous system diseases and shared the potential of engineered exosomes in blood–brain barrier penetration, targeted delivery, and functional RNA delivery. The presentation also highlighted P.S.K Biosciences’ latest progress in building its engineered exosome delivery platform.

Founded in 2016, BIOCHINA is committed to building a global exchange and collaboration platform for the biopharmaceutical industry and has become one of the influential biopharma events in the Asia-Pacific region. P.S.K Biosciences’ participation and presentation at BIOCHINA2026 reflect the Company’s continued efforts in exosome-based therapeutics and engineered delivery technologies.

Moving forward, P.S.K Biosciences will continue to advance its engineered exosome RNA delivery platform and natural exosome therapeutics platform, with the goal of accelerating the translational application of exosome technologies in CNS diseases and other areas with significant unmet medical needs.

P.S.K Biosciences
Corporate Communications
February 28, 2026